Notice2023-02788
National Institute on Drug Abuse; Notice of Closed Meetings
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
February 9, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 27 (Thursday, February 9, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 27 (Thursday, February 9, 2023)]
[Notices]
[Page 8438]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-02788]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Novel Drug and Medical Device Development Tools to
Help Expedite Creation and Regulatory Approvals of New Therapies for
Substance Use Disorders.
Date: March 6, 2023.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 827-5819, <a href="/cdn-cgi/l/email-protection#284f45191c1d4968464140064f475e"><span class="__cf_email__" data-cfemail="13747e22272672537d7a7b3d747c65">[email protected]</span></a>.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Developing Digital Therapeutics for Substance Use
Disorders.
Date: March 13, 2023.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Jenny Raye Browning, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 443-4577,
<a href="/cdn-cgi/l/email-protection#5c3639323225723e2e332b3235323b1c323534723b332a"><span class="__cf_email__" data-cfemail="ff959a919186d19d8d908891969198bf919697d1989089">[email protected]</span></a>.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Pharmacokinetic and Pharmacodynamic Trials for
Medication Development in Substance Use Disorders.
Date: April 5, 2023.
Time: 2:00 p.m. to 2:45 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: Marisa Srivareerat, Ph.D., Scientific Review
Officer, Scientific Review Branch, Office of Extramural Policy,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 435-1258,
<a href="/cdn-cgi/l/email-protection#cda0acbfa4beace3bebfa4bbacbfa8a8bfacb98da3a4a5e3aaa2bb"><span class="__cf_email__" data-cfemail="93fef2e1fae0f2bde0e1fae5f2e1f6f6e1f2e7d3fdfafbbdf4fce5">[email protected]</span></a>.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: February 6, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-02788 Filed 2-8-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on February 9, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.